
Quarterly report 2024-Q3
added 11-12-2024
Psychemedics Corporation Net Debt 2011-2026 | PMD
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Psychemedics Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.41 M | -409 K | 1.49 M | -4.65 M | -2.44 M | -4.79 M | -557 K | 3.2 M | 2.64 M | -3.97 M | -3.07 M | -5.56 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.2 M | -5.56 M | -1.79 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.24 B | $ 114.25 | -1.07 % | $ 34.7 B | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.64 | 3.53 % | $ 85.7 K | ||
|
Biodesix
BDSX
|
14.5 M | $ 15.55 | 3.19 % | $ 2.02 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
1.19 M | $ 1.2 | -0.03 % | $ 6.53 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 16.5 | 1.85 % | $ 178 M | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 18.32 | 0.05 % | $ 976 M | ||
|
Celcuity
CELC
|
-28.1 M | $ 113.8 | 1.04 % | $ 5.32 B | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
-10.6 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 168.44 | -3.13 % | $ 8.35 B | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 24.85 | 0.04 % | $ 690 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 197.89 | 0.37 % | $ 22 B | ||
|
Danaher Corporation
DHR
|
14 B | $ 190.62 | -0.26 % | $ 136 B | ||
|
DexCom
DXCM
|
-842 M | $ 62.7 | 0.76 % | $ 24.5 B | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 16.8 | -0.15 % | $ 508 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
1.15 B | $ 92.35 | -1.58 % | $ 11.6 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 110.38 | -3.34 % | $ 9.1 B | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Illumina
ILMN
|
-494 M | $ 127.63 | 0.2 % | $ 20.3 B | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
IQVIA Holdings
IQV
|
12 B | $ 168.24 | -2.9 % | $ 28.9 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 274.94 | 0.41 % | $ 22.9 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 76.0 | -0.14 % | $ 5.13 B | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 485.89 | -2.5 % | $ 14 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 258.2 | -0.3 % | $ 25.9 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.84 | 1.79 % | $ 448 M | ||
|
ENDRA Life Sciences
NDRA
|
-270 K | $ 4.69 | - | $ 3.69 M | ||
|
NeoGenomics
NEO
|
187 M | $ 8.06 | 0.75 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.42 | 0.11 % | $ 2.04 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 17.35 | 1.11 % | $ 388 M | ||
|
Natera
NTRA
|
-177 M | $ 207.01 | -0.46 % | $ 20.4 B | ||
|
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.36 | 1.49 % | $ 408 M | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 27.09 | -0.07 % | $ 20 B | ||
|
Precipio
PRPO
|
-2.19 M | $ 25.23 | -1.29 % | $ 40.5 M | ||
|
Personalis
PSNL
|
-48.8 M | $ 6.63 | 0.76 % | $ 393 M | ||
|
RadNet
RDNT
|
359 M | $ 55.12 | 0.6 % | $ 4.14 B |